OMC
PRME icon

OUP Management Company’s Prime Medicine PRME Stock Holding History

OUP Management Company’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-121,255
Closed -$1.49M – 14
2023
Q1 		$1.49M Hold
121,255
– – 2.98% 8
2022
Q4 		$2.25M Buy
+121,255
New +$2.19M 3.68% 8

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

OUP Management Company's PRME Position: Q2 2023 in Review

OUP Management Company sold out of Prime Medicine (PRME) in Q2 2023, closing a stake of 121,255 shares — an estimated $1.49M sold.

OUP Management Company first reported a position in PRME in Q4 2022 and held it in 2 quarters. The position peaked at $2.25M in Q4 2022. 79 funds tracked by Wall St. Rank hold PRME as of Q2 2023.

  • OUP Management Company reported no remaining Prime Medicine position as of Q2 2023 after selling out during the quarter.
  • OUP Management Company sold 121,255 Prime Medicine shares in Q2 2023, an estimated $1.49M.
  • OUP Management Company first reported a position in Prime Medicine in Q4 2022 and held it in 2 quarters.
  • OUP Management Company's Prime Medicine position peaked at $2.25M in Q4 2022.
  • 79 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2023.

Based on OUP Management Company's 13F filing for Q2 2023, filed 7 Aug 2023.